Van Neste D, Rihoux J P
Department of Dermatology, Université Catholique de Louvain, Brussels.
Skin Pharmacol. 1988;1(3):192-9.
A controlled, randomized, double-blind, cross-over study was performed in 10 healthy volunteers in order to compare changes of cutaneous blood flow values (CBFV, laser Doppler flowmetry, Periflux, Perimed, S) in histamine-challenged skin before and after administration of a capsule containing either 10 mg cetirizine or 60 mg terfenadine. The overall pattern of the basal cutaneous wheal and flare response to the agonists (histamine: aqueous solution: Hsol, or Phazet: Hprick) and control saline solution, showed the expected range of clinical effects, i.e. Hsol greater than Hprick greater than saline. Similarly, the increase of CBFV on the flare area was higher around the histamine injections as compared with saline. Surprisingly, CBFV was decreased at the site of Hsol and Hprick injections as compared with the levels recorded at the control injections. The following changes were noted after intake of H1-blocking agents. (1) There was a reduction of the areas of wheal and flare at all injection sites after administration of the H1 blockers, this reduction being consistently greater under cetirizine than terfenadine. (2) CBFV, measured 1 cm from the site of Hsol injection (i.e., within the area of normal flare response), was decreased only with cetirizine. In the smaller flare area induced by Hprick, CBFV was equally suppressed by both drugs. (3) At the site of agonist injection, along with a reduction of the size of the wheal, we observed significant increases in CBFV after drug intake. Under these experimental conditions, this quantitative pharmacologic in vivo assay of agonist-antagonist interactions suggests that after initial administration of normally prescribed doses, cetirizine may possess more anti-H1 activity than terfenadine.
对10名健康志愿者进行了一项对照、随机、双盲、交叉研究,以比较在给予含10毫克西替利嗪或60毫克特非那定的胶囊前后,组胺激发皮肤中皮肤血流值(CBFV,激光多普勒血流仪,Periflux,Perimed,S)的变化。对激动剂(组胺:水溶液:Hsol,或Phazet:Hprick)和对照盐溶液的基础皮肤风团和潮红反应的总体模式显示出预期的临床效应范围,即Hsol大于Hprick大于盐水。同样,与盐水相比,组胺注射周围潮红区域的CBFV增加更高。令人惊讶的是,与对照注射记录的水平相比,Hsol和Hprick注射部位的CBFV降低。服用H1阻滞剂后观察到以下变化。(1)服用H1阻滞剂后,所有注射部位的风团和潮红面积均减小,西替利嗪治疗下的这种减小始终大于特非那定。(2)在距Hsol注射部位1厘米处(即在正常潮红反应区域内)测量的CBFV仅在使用西替利嗪时降低。在Hprick诱导的较小潮红区域,两种药物均同等程度地抑制了CBFV。(3)在激动剂注射部位,随着风团大小的减小,我们观察到服药后CBFV显著增加。在这些实验条件下,这种激动剂 - 拮抗剂相互作用的定量药理学体内试验表明,在最初给予正常规定剂量后,西替利嗪可能比特非那定具有更多的抗H1活性。